Mereo BioPharma Group plc (MREO) stock
Close on Nov 17, 2026Market cap $43.84MP/E –Yield –
Mereo BioPharma Group plc reported revenue of $500.00K for fiscal 2025. Free cash flow was -$22.09M. At the latest close the market valued the company at $43.84M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $43.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.85
- Dividend yield
- –
- Free cash flow yield
- -50.39%
Fundamentals
- Revenue
- $500.00K
- Net income
- -$26.94M
- EPS, diluted
- -$0.04
- Free cash flow
- -$22.09M
- Book value per share
- $0.03
- Diluted shares
- 805M
Trading
- Next earnings
- Mar 18, 2027 (estimated, before the open)
- Previous close
- $0.30
- Open
- $0.30
- Day's range
- $0.27 – $0.30
- Volume
- 1,038,163
- Average volume (20 days)
- 683,750
- 52-week range
- $0.20 – $2.37
- RSI (14 days)
- 39.5
- Volatility (1 year)
- 131.9%
- Relative volume
- 0.34×
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | MREO | S&P 500 | Difference | MREO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.4% | -4.0% | −5.4 pts | ||
| 3 months | -10.8% | -5.0% | −5.8 pts | ||
| Year to date | -34.1% | +8.2% | −42.4 pts | ||
| 1 year | -84.5% | +11.2% | −95.7 pts | ||
| 3 years | -86.8% | +68.5% | −155.3 pts | -49.1% | +19.0% |
| 5 years | -86.6% | +67.3% | −153.9 pts | -33.1% | +10.8% |
| 10 years | +2645.0% | +291.6% | +2353.4 pts | +39.3% | +14.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Mereo BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About Mereo BioPharma
Pharmaceutical Preparations
Mereo BioPharma Group plc is a biopharmaceutical company that develops therapeutics for rare diseases. The organization acquires drug candidates with prior development history from larger pharmaceutical corporations to advance clinical programs. Its principal late-stage clinical assets include setrusumab, a monoclonal antibody under evaluation for osteogenesis imperfecta, and alvelestat, an oral neutrophil elastase inhibitor designed for alpha-1 antitrypsin deficiency-associated lung disease. It also maintains vantictumab for autosomal dominant osteopetrosis Type 2. The company focuses on clinical-stage segments, serving patient populations with specialized medical conditions and collaborating with commercial biopharmaceutical partners.
Company profile, executives and historyMereo BioPharma stock: common questions
What is Mereo BioPharma's stock price?
MREO closed at $0.27 on Nov 17, 2026, down 10.00% on the day. Over the past 52 weeks it traded between $0.20 and $2.37.
What is Mereo BioPharma's market cap?
Mereo BioPharma was worth $43.84M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is MREO's P/E ratio?
Mereo BioPharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
How much revenue does Mereo BioPharma make?
Mereo BioPharma reported revenue of $500.00K for fiscal 2025.
Does Mereo BioPharma pay a dividend?
No. Mereo BioPharma has not paid a cash dividend over the last twelve months.
When does Mereo BioPharma report earnings next?
Mereo BioPharma is expected to report Q4 FY2026 results on Mar 18, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MREO stock performed over the past year?
Including dividends, MREO returned -84.5% over the past year, against +11.2% for the S&P 500.
Who are Mereo BioPharma's competitors?
Companies most similar to Mereo BioPharma by business, industry and size include RLYB, SLN, XTLB, SCNX, SPRB.
See a number that looks wrong?